Keywords: Novartis, Fougera, Sandoz, Generic dermatological products, M&A

Novartis to buy US generic derma company Fougera for over $1.5 billion

Article | 03 May 2012

Print This

Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its franchise with a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in